M. Yamasaki

Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial.

Y. Nishida, N. Yoshida, H. Ueda, 2016, American heart journal.